

# CHAMOT

## Annexin V-iFluor 488/PI Apoptosis Detection Reagent 细胞凋亡检测试剂盒

CM001-DS

CM001-50D

CM001-100D



CHAMOT

乔默®生物

*Specialize In Cytokines*

# CONTENT

1 产品简介

2 产品使用

3 产品储存/运输

4 文献引用

## Annexin V-iFluor 488/PI Apoptosis Detection Reagent 细胞凋亡检测试剂盒

|      |          |           |            |
|------|----------|-----------|------------|
| 产品编号 | CM001-DS | CM001-50D | CM001-100D |
| 规格   | 15 rxn   | 50 rxn    | 100 rxn    |

### 产品简介

#### 背景描述

Annexin V 是一种钙离子依赖性磷脂结合蛋白，与磷脂酰丝氨酸 PS 有高度亲和力，可通过细胞外侧暴露的 PS 与凋亡早期细胞膜结合，将 Annexin V 标记荧光染料 iFluor488(Ex:488nm, Em:514nm)，利用流式细胞仪或荧光显微镜可检测细胞凋亡。PI 是一种细胞核染料，搭配 Annexin V 使用可将处于不同凋亡时期的细胞区分开。

#### 产品形式

液体

#### 产品应用

Apoptosis Assays

### 产品使用

| 试剂盒组分                | CM001-50D | CM001-100D |
|----------------------|-----------|------------|
| Annexin V-iFluor 488 | 1×0.25 mL | 1×0.5 mL   |
| PI Solution          | 1×0.25 mL | 1×0.5 mL   |
| 10×Binding Buffer    | 2×2 mL    | 3×2 mL     |

本试剂盒可应用于培养细胞凋亡检测（不推荐用于检测组织样本）。

#### 流式细胞实验操作步骤：

1. 悬浮细胞离心（2000 rpm离心5分钟）收集；贴壁细胞用不含 EDTA 的胰酶消化收集。
2. 用PBS洗涤细胞两次（2000 rpm离心5分钟）收集 $1-5 \times 10^6$ 细胞。
3. 用去离子水按照1：9稀释Binding Buffer（1 ml 10×Binding Buffer+9 ml 去离子水）。
4. 加入500  $\mu$ L 1×Binding Buffer重悬细胞。
5. 加入5  $\mu$ L AnnexinV-iFluor488混匀后加入5  $\mu$ L PI混匀，室温避光反应15-20分钟。
6. 孵育后将样本置于冰上，准备进行流式检测。

## 产品储存/运输

**储存** 4℃避光，有效期两年

**运输** 蓝冰

## 文献引用

- Effect of Metformin Nanoparticle-Mediated Thioredoxin Interacting Protein Expression on Oxaliplatin-Induced Peripheral Neuralgia. J Nanosci Nanotechnol. 2020 Oct 1;20(10):6123-6132. (IF 1.42)
- Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Delivery. 2022, VOL. 29, NO. 1, 937-949. (IF 6.419)
- A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin. J Nanobiotechnology. 2022 May 14;20(1):230. (IF 9.464)
- Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage. Front Pharmacol. 2022 Aug 11;13:949835. (IF 5.81)
- Targeted photodynamic therapy of glioblastoma mediated by platelets with photo-controlled release property. Biomaterials. 2022 Sep 30;290:121833. (IF 15.304)
- Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition. Hepatology. 2023 Jan 3. (IF 17.298)
- Chlorin e6-induced photodynamic effect facilitates immunogenic cell death of lung cancer as a result of oxidative endoplasmic reticulum stress and DNA damage. Int Immunopharmacol. 2023 Feb;115:109661. (IF 5.714)
- Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy. Phytomedicine. 2023 Apr;112:154682. (5.34)
- Laser-triggered intelligent drug delivery and anti-cancer photodynamic therapy using platelets as the vehicle. Platelets. 2023 Dec;34(1):2166677. (IF 4.236)
- Up-regulation of ABCG2 by MYBL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer. Photodiagnosis Photodyn Ther. 2023 Apr 6;103558. (IF 3.577)
- Sonodynamic therapy of glioblastoma mediated by platelets with ultrasound-triggered drug release. Drug Deliv. 2023 Dec;30(1):2219429. (IF 6.819)
- MiR-934 Exacerbates Malignancy of Gastric Cancer Cells by Targeting ZFP36. Iran J Public Health. 2023;52(8):1720-1729. (IF 1.4)
- A Dihydroartemisinin-Loaded Nanoreactor Motivates Anti-Cancer Immunotherapy by Synergy-Induced Ferroptosis to Activate Cgas/STING for Reprogramming of Macrophage. Adv Healthc Mater.

2023 Aug 11;e2301561. (IF 11.092)

- Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus. *Drug Deliv Transl Res.* 2024 Apr 10. (IF 5.4)
- Dihydroartemisinin-driven TOM70 inhibition leads to mitochondrial destabilization to induce pyroptosis against lung cancer. *Phytother Res.* 2024 May 18. (IF 6.1)
- Targeted Sonodynamic Therapy Induces Tumor Cell Quasi-Immunogenic Ferroptosis and Macrophage Immunostimulatory Autophagy in Glioblastoma. *Biomaterials.* Volume 315, April 2025, 122913. (IF 12.8)
- Suppression of NRF2 by photodynamic action to enhance bortezomib-triggered DNA damage for synergistic colorectal cancer therapy. *J Photochem Photobiol B.* 2025 Jun;267:113162. (IF 4.5)
- Accelerated differentiation of photothermal effect-induced mesenchymal stem cells regulated by activating HSP90-autophagy boosts wound repair. *Int J Pharm.* 2025 May 15;676:125631. (IF 5.77)
- Using Metal-Organic Framework Nanoparticles for Targeted Codelivery of Bortezomib and Iron Ions to Mitochondrial TOM20 to Induce Ferroptosis for Colorectal Cancer Treatment. *Mol Pharm.* 2025 Aug 4;22(8):4865-4878.( IF 4.5)
- Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. *ACS Pharmacol. Transl. Sci.* 2025, 8, 8, 2710–2724. ( IF 3.7)

For Research Use or Further Manufacturing Only

Chamot Biotechnology(Shanghai) Co., Ltd. [www.chamot-bio.com](http://www.chamot-bio.com)

Tel: 021-51880030    Mail: [info@chamot-bio.com](mailto:info@chamot-bio.com)    QQ: 864920491